文献速递肝病

抑制ACMSD可纠正MASLD/MASH中的纤维化、炎症和DNA损伤

ACMSD inhibition corrects fibrosis, inflammation, and DNA damage in MASLD/MASH.
PubMed 文献 · J Hepatol · 2024-08-22

本研究在体外原代啮齿类肝细胞、Huh7细胞和人肝类器官及西方饮食喂养的C57BL/6J雄性小鼠中,探讨药理抑制ACMSD对MASLD/MASH的治疗作用。结果显示抑制ACMSD可促进肝脏从头NAD+合成、增加肝NAD+并逆转小鼠MASLD/MASH,减轻纤维化、炎症和DNA损伤;人肝类器官模型亦观察到DNA损伤应答改善。作者认为ACMSD是MASLD/MASH管理的 promising 靶点,为开发ACMSD抑制剂作为临床治疗奠定基础。

要点

  • 药理抑制ACMSD可促进肝脏从头NAD+合成并减少DNA损伤。
  • 小鼠MASLD/MASH模型中抑制ACMSD可增加肝NAD+并逆转疾病,减轻纤维化、炎症和DNA损伤。
  • 作者认为ACMSD是MASLD/MASH有前景的靶点,为ACMSD抑制剂临床开发奠定基础。

核心结论

  • 研究结果强调抑制ACMSD可提高肝脏NAD+水平并实现基因组保护,凸显其在MASLD/MASH中的治疗潜力。
  • 临床前研究认定ACMSD是MASLD/MASH管理的有前景靶点,为开发ACMSD抑制剂作为临床治疗奠定基础。

研究设计与样本

  • 体外实验在原代啮齿类肝细胞、Huh7人肝癌细胞和诱导多能干细胞来源的人肝类器官(HLO)中进行。
  • C57BL/6J雄性小鼠喂以西式饮食并置于热中性环境饲养以复现MASLD/MASH关键特征,疾病起病后给予药理ACMSD抑制治疗。
  • 采用HLO脂肪性肝炎模型评估ACMSD抑制在人源背景下的DNA损伤应答。

主要发现

  • 使用新型特异性药理抑制剂抑制ACMSD可在离体、体内和HLO模型中促进从头NAD+合成并减少DNA损伤。
  • 小鼠MASLD/MASH模型中从头NAD+生物合成受抑制,转录组DNA损伤特征与疾病严重程度相关。
  • 人类孟德尔随机化遗传分析提示基因组应激对肝病易感性有显著影响。
  • 小鼠治疗性抑制ACMSD可增加肝NAD+并逆转MASLD/MASH,减轻纤维化、炎症和DNA损伤,HLO脂肪性肝炎模型亦观察到类似效果。
  • 抑制ACMSD可增加NAD+水平、增强线粒体呼吸并维持肝细胞基因组稳定性(离体和体内)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Recent findings reveal the importance of tryptophan-initiated de novo nicotinamide adenine dinucleotide (NAD+) synthesis in the liver, a process previously considered secondary to biosynthesis from nicotinamide. The enzyme α-amino-β-carboxymuconate-ε-semialdehyde decarboxylase (ACMSD), primarily expressed in the liver and kidney, acts as a modulator of de novo NAD+ synthesis. Boosting NAD+ levels has previously demonstrated remarkable metabolic benefits in mouse models. In this study, we aimed to investigate the therapeutic implications of ACMSD inhibition in the treatment of metabolic dysfunction-associated steatotic liver disease/steatohepatitis (MASLD/MASH). METHODS: In vitro experiments were conducted in primary rodent hepatocytes, Huh7 human liver carcinoma cells and induced pluripotent stem cell-derived human liver organoids (HLOs). C57BL/6J male mice were fed a western-style diet and housed at thermoneutrality to recapitulate key aspects of MASLD/MASH. Pharmacological ACMSD inhibition was given therapeutically, following disease onset. HLO models of steatohepatitis were used to assess the DNA damage responses to ACMSD inhibition in human contexts. RESULTS: Inhibiting ACMSD with a novel specific pharmacological inhibitor promotes de novo NAD+ synthesis and reduces DNA damage ex vivo, in vivo, and in HLO models. In mouse models of MASLD/MASH, de novo NAD+ biosynthesis is suppressed, and transcriptomic DNA damage signatures correlate with disease severity; in humans, Mendelian randomization-based genetic analysis suggests a notable impact of genomic stress on liver disease susceptibility. Therapeutic inhibition of ACMSD in mice increases liver NAD+ and reverses MASLD/MASH, mitigating fibrosis, inflammation, and DNA damage, as observed in HLO models of steatohepatitis. CONCLUSIONS: Our findings highlight the benefits of ACMSD inhibition in enhancing hepatic NAD+ levels and enabling genomic protection, underscoring its therapeutic potential in MASLD/MASH. IMPACT AND IMPLICATIONS: Enhancing NAD+ levels has been shown to induce remarkable health benefits in mouse models of metabolic dysfunction-associated steatotic liver disease/steatohepatitis (MASLD/MASH), yet liver-specific NAD+ boosting strategies remain underexplored. Here, we present a novel pharmacological approach to enhance de novo synthesis of NAD+ in the liver by inhibiting α-amino-β-carboxymuconate-ε-semialdehyde decarboxylase (ACMSD), an enzyme highly expressed in the liver. Inhibiting ACMSD increases NAD+ levels, enhances mitochondrial respiration, and maintains genomic stability in hepatocytes ex vivo and in vivo. These molecular benefits prevent disease progression in both mouse and human liver organoid models of steatohepatitis. Our preclinical study identifies ACMSD as a promising target for MASLD/MASH management and lays the groundwork for developing ACMSD inhibitors as a clinical treatment.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Liu YJ, Kimura M, Li X, et al. ACMSD inhibition corrects fibrosis, inflammation, and DNA damage in MASLD/MASH. J Hepatol. 2024. PMID: 39181211. doi:10.1016/j.jhep.2024.08.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。